Table 1.
Summary of epidemiological and clinical characteristics in HCV-monoinfected patients and HIV/HCV-coinfected patients who had advanced HCV-related cirrhosis.
| All | HCV | HIV/HCV | p-values | |
|---|---|---|---|---|
| No. | 97 | 32 | 65 | |
| Gender (male) (n = 97) | 68 (70.1%) | 18 (56.3%) | 50 (76.9%) | 0.037 |
| Age (years) (n = 97) | 53 (48.8; 56.5) | 59.5 (52.6; 70) | 51.8 (48.7; 53.8) | <0.001 |
| Smoker (n = 96) | ||||
| Never | 19 (19.8%) | 11 (34.4%) | 8 (12.5%) | 0.589 |
| Previously (≥ 6 months) | 25 (26%) | 10 (31.3%) | 15 (23.4%) | 0.988 |
| Nowadays | 52 (54.2%) | 11 (34.4%) | 41 (64.1%) | 0.153 |
| Alcohol intake (n = 97) | ||||
| Never | 49 (50.5%) | 22 (68.8%) | 27 (41.5%) | 0.105 |
| Previously (≥ 6 months) | 40 (41.2%) | 9 (28.1%) | 31 (47.7%) | 0.507 |
| Nowadays | 8 (8.2%) | 1 (3.1%) | 7 (10.8%) | 0.120 |
| IVDU (n = 97) | ||||
| Never | 40 (41.2%) | 27 (84.4%) | 13 (20%) | <0.001 |
| Previously (≥ 6 months) | 57 (58.8%) | 5 (15.6%) | 52 (80%) | 0.009 |
| Current | 0 (0%) | 0 (0%) | 0 (0%) | — |
| Treatments | ||||
| Previous IFNα therapy (n = 97) | 49 (50.5%) | 21 (65.6%) | 28 (43.1%) | 0.037 |
| Statins (n = 97) | 11 (11.3%) | 1 (3.1%) | 10 (15.4%) | 0.073 |
| Antiretroviral therapy (n = 65) | ||||
| NRTI + NNRTI-based | — | — | 7 (10.8%) | |
| NRTI + II-based | — | — | 34 (52.3%) | |
| NRTI + PI-based | — | — | 9 (13.8%) | |
| PI + II + others-based | — | — | 4 (6.2%) | |
| Others | — | — | 11 (16.9%) | |
| HIV markers | ||||
| Prior AIDS (n = 65) | — | — | 23 (35.4%) | |
| Nadir CD4 + T-cells (cells/mm3) (n = 60) | — | — | 129 (70; 243.5) | |
| Nadir CD4 + < 200 cells/mm3 (n = 60) | — | — | 40 (66.7%) | |
| CD4 + T-cells (cells/mm3) (n = 65) | — | — | 444 (234; 719) | |
| CD4 + < 500 cells/mm3 (n = 65) | — | — | 38 (58.5%) | |
| Undetectable HIV-RNA (n = 65) | — | — | 65 (100%) | |
| HCV markers | ||||
| HCV genotype (n = 95) | ||||
| 1 | 65 (68.4%) | 25 (78.1%) | 40 (63.5%) | 0.335 |
| 3 | 14 (14.7%) | 4 (12.5%) | 10 (15.9%) | 0.503 |
| 4 | 16 (16.8%) | 3 (9.4%) | 13 (20.6%) | 0.708 |
| Log10 HCV-RNA (IU/mL) (n = 96) | 6.1 (5.5; 6.5) | 6.1 (5.4; 6.4) | 6.2 (5.6; 6.6) | 0.287 |
| HCV-RNA ≥ 850.000 IU/mL | 60 (62.5%) | 19 (59.4%) | 41 (64.1%) | 0.655 |
| Liver disease (n = 94) | ||||
| LSM (kPa) | 30.6 (24.5; 41.6) | 29.9 (26.3; 48) | 31 (22.3; 39.3) | 0.208 |
| <25 kPa | 24 (25.5%) | 6 (19.4%) | 18 (28.6%) | 0.926 |
| 25–40 kPa | 45 (47.9%) | 14 (45.2%) | 31 (49.2%) | 0.941 |
| ≥40 kPa | 25 (26.6%) | 11 (35.5%) | 14 (22.2%) | 0.774 |
| Child-Pugh Score (n = 91) | 5 (5; 6) | 5 (5; 7) | 5 (5; 5) | 0.012 |
| Child-Pugh B (7–9) | 13 (14.3%) | 8 (28.6%) | 5 (7.9%) | 0.009 |
| Prior history of liver decompensation | 30 (31%) | 8 (22.8%) | 22 (33.8%) | 0.375 |
Statistics: Values expressed as absolute number (percentage) and median (interquartile range). P-values were calculated by Chi-square, Fisher’s exact test, and Mann-Whitney tests, as required. The statistically significant differences are shown in bold.
Abbreviations: HCV, hepatitis C virus; HIV, human immunodeficiency virus; IVDU, intravenous drug user; IFNα, interferon-alpha; NRTI, nucleoside analogue HIV reverse; NNRTI, non-nucleoside analogue HIV reverse transcriptase inhibitor; PI, protease inhibitor; II, integrase inhibitor; AIDS, acquired immune deficiency syndrome; HIV-RNA, HIV plasma viral load; HCV-RNA, HCV plasma viral load; LSM, liver stiffness measure; kPa, kilopascal.